PCAT6 and non-small cell lung carcinoma: Moreover, in NSCLC, PCAT6 transcriptionally impairs large tumor suppressor kinase 2 (LATS2) promoter activity by binding to EZH2, which mediates H3K27 trimethylation and accelerates the cell cycle, promoting cell proliferation, tumor growth and metastasis, and hindering cell apoptosis [40].